MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Edge Therapeutics Company Profile (NASDAQ:EDGE)

Consensus Ratings for Edge Therapeutics (NASDAQ:EDGE) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.50 (156.26% upside)

Analysts' Ratings History for Edge Therapeutics (NASDAQ:EDGE)
Show:
DateFirmActionRatingPrice TargetActions
5/9/2016Credit SuisseLower Price TargetOutperform$19.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Leerink SwannReiterated RatingOutperform$27.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$34.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015GuggenheimInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Edge Therapeutics (NASDAQ:EDGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/3/2016        
5/3/2016($0.34)($0.32)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Edge Therapeutics (NASDAQ:EDGE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.42)($0.42)($0.42)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)
Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Edge Therapeutics (NASDAQ:EDGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Edge Therapeutics (NASDAQ:EDGE)
DateHeadline
06/26/16 08:45 AMEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorts Decreased by 5.26% After Short Covering - Engelwood Daily
06/24/16 03:51 PMJRJR NETWORKS TO HOLD SHAREHOLDER CALL TODAY AT 5 : 30 pm Eastern Time
06/24/16 03:51 PMForm 4 Edge Therapeutics, Inc. For: Jun 21 Filed by: New Leaf Venture Partners, L.L.C.
06/24/16 03:17 PMEDGE THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/24/16 12:10 PMEdge Therapeutics Granted U.S. Patent Covering the Expanded Use of Lead Candidate EG-1962 - [at noodls] - BERKELEY HEIGHTS , N.J., June 24, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinicalstage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening ...
06/24/16 10:31 AMForm 4 Edge Therapeutics, Inc. For: Jun 21 Filed by: New Leaf Venture Partners, LLC - StreetInsider.com
06/23/16 08:47 PMHow Many Edge Therapeutics Inc (NASDAQ:EDGE)'s Analysts Are Bullish? - Engelwood Daily
06/23/16 08:47 PMForm 4 Edge Therapeutics, Inc. For: Jun 21 Filed by: Conti Kurt G - StreetInsider.com
06/23/16 02:42 PMForm 4 Edge Therapeutics, Inc. For: Jun 21 Filed by: BLECH ISAAC - StreetInsider.com
06/23/16 06:51 AMEdge Therapeutics, Inc. (NASDAQ:EDGE) Current Analyst Ratings - Fiscal Standard
06/18/16 08:19 AMRecently Issued Stock Ratings For Edge Therapeutics, Inc. (NASDAQ:EDGE) - Fiscal Standard
06/10/16 03:52 PMWill Edge Therapeutics (EDGE) Continue to Surge Higher? - Nasdaq
06/10/16 11:09 AMEdge Therapeutics’ Chief Accounting and Operations Officer Bert Marchio Receives the New Jersey Tech Council Deal of the Year Award - [at noodls] - MONROE TOWNSHIP, N.J., June 10, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening ...
06/10/16 08:19 AMWill Edge Therapeutics (EDGE) Continue to Surge Higher?
06/03/16 04:01 PMBroker Watchlist: Edge Therapeutics, Inc. (NASDAQ:EDGE) - Share Trading News
06/02/16 09:50 PMAre Analysts Bearish Edge Therapeutics Inc (NASDAQ:EDGE) After Last Week? - HNN - Are Analysts Bearish Edge Therapeutics Inc (NASDAQ:EDGE) After Last Week?HNNOut of 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Edge Therapeutics has been the topic of 4 analyst reports since October 26, 2015 according to StockzIntelligence Inc.and more »
06/02/16 12:03 PMEdge Therapeutics, Inc. :EDGE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/02/16 08:11 AMEdge Therapeutics (EDGE) Catches Eye: Stock Soars 19.4% - Nasdaq - Edge Therapeutics (EDGE) Catches Eye: Stock Soars 19.4%NasdaqEdge Therapeutics, IncEDGE was a big mover last session, as the company saw its shares rise over 19% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the ...
06/02/16 08:11 AMCan Edge Therapeutics Inc. (NASDAQ:EDGE) Survive? - Scibility Media - Scibility MediaCan Edge Therapeutics Inc. (NASDAQ:EDGE) Survive?Scibility MediaEdge Therapeutics Inc. (NASDAQ: EDGE) is enjoying some regulatory priorities in the development of aneurysmal subarachnoid hemorrhage (aSAH) treatment EG-1962. The FDA has granted the compound both Fast-Track and Orphan drug designations.Edge Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire (press release)all 2 news articles »
06/02/16 07:00 AMEdge Therapeutics (EDGE) Catches Eye: Stock Soars 19.4% -
06/02/16 06:45 AMEdge Therapeutics to Present at Upcoming Investor Conferences - [at noodls] - BERKELEY HEIGHTS, N.J., June 02, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, ...
05/25/16 11:03 AMBroker Roundup For Edge Therapeutics, Inc. (NASDAQ:EDGE) - Share Trading News - Broker Roundup For Edge Therapeutics, Inc. (NASDAQ:EDGE)Share Trading News03/08/2016 – Edge Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 24 price target on the stock. 10/26/2015 – Guggenheim began new coverage on Edge Therapeutics, Inc. giving the company a ...and more »
05/20/16 11:31 AMCredit Suisse Maintains Edge Therapeutics Inc to Outperform with Price Target $18.00 - Trade Calls - Credit Suisse Maintains Edge Therapeutics Inc to Outperform with Price Target $18.00Trade CallsBrokerage firm Credit Suisse Maintains its rating on Edge Therapeutics Inc(NASDAQ:EDGE). In a research note issued to the investors, the brokerage major Lowers the price-target to $18.00 per share. The shares have been rated Outperform. The rating by ...Edge Therapeutics, Inc. (NASDAQ:EDGE) Updated Broker Price TargetsShare Trading NewsRecently Changed Price Targets On Edge Therapeutics, Inc. (NASDAQ:EDGE)Risers & Fallersall 35 news articles »
05/16/16 02:46 PMEDGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/16/16 10:54 AMKeep An Eye On EYEG, SCYX Awaits Data In June, VBLT On The Move - (RTTNews.com) - Edge Therapeutics Inc.'s ( EDGE) drug candidate EG-1962 has been granted Fast Track designation for the treatment of subarachnoid hemorrhage. The company expects to begin enrollment in a pivotal phase III of EG-1962 in adults with ...
05/14/16 10:52 AMInvestors' Radars Failed to Catch Edge Therapeutics (EDGE), Has Yours? - Nasdaq - Investors' Radars Failed to Catch Edge Therapeutics (EDGE), Has Yours?NasdaqOne such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Edge Therapeutics, Inc. EDGE . This Medical-Biomedical/Genetics stock has actually seen loss estimates narrow over the past month for the ...
05/14/16 10:52 AMEdge Therapeutics Receives FDA Fast Track Designation for EG-1962 for the Treatment of Subarachnoid Hemorrhage - Nasdaq - Edge Therapeutics Receives FDA Fast Track Designation for EG-1962 for the Treatment of Subarachnoid HemorrhageNasdaqBERKELEY HEIGHTS, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today ...and more »
05/13/16 06:38 AMEdge Therapeutics Receives FDA Fast Track Designation for EG-1962 for the Treatment of Subarachnoid Hemorrhage - [at noodls] - BERKELEY HEIGHTS, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, ...
05/12/16 08:00 AMInvestors' Radars Failed to Catch Edge Therapeutics (EDGE), Has Yours? -
05/11/16 10:49 AMThree Big Pharma Stocks Headed Higher - while lowering our target price for Edge Therapeutics ( EDGE EDGE 4.834905660377358% Edge Therapeutics Inc. U.S.: Nasdaq USD 8.89 0.41 4.834905660377358% /Date(1462914000171-0500)/ Volume (Delayed 15m) : 57710 P/E Ratio N/A Market Cap 244342699.822693 ...
05/10/16 12:04 PMEDGE THERAPEUTICS, INC. Financials -
05/10/16 10:58 AMTop News: Entertainment Gaming Asia (NASDAQ:EGT), Edge Therapeutics (NASDAQ:EDGE), Federal Agricultural ... - KC Register - KC RegisterTop News: Entertainment Gaming Asia (NASDAQ:EGT), Edge Therapeutics (NASDAQ:EDGE), Federal Agricultural ...KC RegisterEdge Therapeutics, Inc. (NASDAQ:EDGE) announced financial results and highlights for the three months ended March 31, 2016. General and administrative expenses were $3.7 million for the three months ended March 31, 2016 compared to $1.3 million in ...and more »
05/06/16 09:14 AMEdge Therapeutics Chief Financial Officer Andrew J. Einhorn Receives CFO Studio 2016 CFO Success Award - [at noodls] - RUTHERFORD, N.J., May 6, 2016 - Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management of acute, life- threatening conditions, ...
05/04/16 10:28 AMBRIEF-Edge Therapeutics reports quarterly loss per share $0.32 - Reuters - BRIEF-Edge Therapeutics reports quarterly loss per share $0.32ReutersBRIEF-Edge Therapeutics reports quarterly loss per share $0.32. May 3 Edge Therapeutics Inc. * Qtrly loss per share $0.32. * Q1 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bengaluru ...
05/03/16 10:34 AMBroker Outlook For The Week Ahead: Edge Therapeutics, Inc. (NASDAQ:EDGE) - Share Trading News - Broker Outlook For The Week Ahead: Edge Therapeutics, Inc. (NASDAQ:EDGE)Share Trading News03/08/2016 – Edge Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 24 price target on the stock. 10/26/2015 – Guggenheim began new coverage on Edge Therapeutics, Inc. giving the company a ...and more »
05/03/16 10:34 AMEdge Therapeutics Reports First Quarter 2016 Financial Results - Nasdaq - Edge Therapeutics Reports First Quarter 2016 Financial ResultsNasdaqBERKELEY HEIGHTS, N.J. , May 03, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management of acute, life threatening conditions, today ...and more »
05/03/16 10:34 AMEdge Therapeutics Inc Earnings Call (Q1 2016) - Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product includes EG-1962, a polymer-based microparticle used for ...
05/03/16 07:30 AMEdge Therapeutics Inc Earnings Call scheduled for 8:30 am ET today -
05/03/16 07:28 AMEdge Therapeutics reports 1Q loss -
05/03/16 06:11 AM7:11 am Edge Therapeutics reports Q1 EPS of ($0.32) vs ($0.34) Capital IQ Consensus Estimate; co did not report any revs -
05/03/16 06:10 AMEdge Therapeutics Reports First Quarter 2016 Financial Results - [at noodls] - BERKELEY HEIGHTS, N.J. , May 03, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management of acute, ...
05/03/16 06:07 AMQ1 2016 Edge Therapeutics Inc Earnings Release - Time Not Supplied -
05/02/16 11:34 AMEdge Therapeutics, Inc. (NASDAQ:EDGE) To Report Earnings Tomorrow - Share Trading News - Edge Therapeutics, Inc. (NASDAQ:EDGE) To Report Earnings TomorrowShare Trading NewsThe biggest institutional shareholders in Edge Therapeutics, Inc. include Fidelity Management and Research Company which owns 3 million shares in the company valued at $36.28 million. Sofinnova Venture Partners IX LP is the second biggest holder with ...and more »
04/29/16 10:38 AMAre Analysts Bearish Edge Therapeutics Inc (NASDAQ:EDGE) After Last Week? - B.O.D.Y Confidential - Are Analysts Bearish Edge Therapeutics Inc (NASDAQ:EDGE) After Last Week?B.O.D.Y ConfidentialOut of 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Edge Therapeutics has been the topic of 4 analyst reports since October 26, 2015 according to StockzIntelligence Inc.and more »
04/26/16 11:15 AMEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorted Shares Increased 5.37% After Market Selling - The Post - Edge Therapeutics Incorporated (NASDAQ:EDGE) Shorted Shares Increased 5.37% After Market SellingThe PostThe short interest to Edge Therapeutics Incorporated's float is 5.75%. The stock increased 2.58% or $0.23 during the last trading session, hitting $9.13. Edge Therapeutics Inc (NASDAQ:EDGE) has risen 6.00% since March 27, 2016 and is uptrending.and more »
04/26/16 11:15 AMEdge Therapeutics to Host a Conference Call on May 3, 2016 to Discuss First Quarter 2016 Financial Results - GlobeNewswire (press release) - Edge Therapeutics to Host a Conference Call on May 3, 2016 to Discuss First Quarter 2016 Financial ResultsGlobeNewswire (press release)BERKELEY HEIGHTS, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today ...and more »
04/26/16 08:31 AMEdge Therapeutics to Host a Conference Call on May 3, 2016 to Discuss First Quarter 2016 Financial Results - [at noodls] - BERKELEY HEIGHTS, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management of acute, ...
04/23/16 10:30 AMEdge Therapeutics, Inc. (NASDAQ:EDGE) Latest Broker Views - Risers & Fallers - Edge Therapeutics, Inc. (NASDAQ:EDGE) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Edge Therapeutics, Inc. (NASDAQ:EDGE). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 ...
04/22/16 11:23 AMPeek Under The Hood: EQWS Has 18% Upside - Three of EQWS's underlying holdings with notable upside to their analyst target prices are Edge Therapeutics Inc (EDGE), Everi Holdings Inc (EVRI), and Ignyta Inc (RXDX). Although EDGE has traded at a recent price of $9.08/share, the average analyst target ...
04/16/16 10:21 AMEdge Therapeutics Incorporated (NASDAQ:EDGE) Short Interest Increased By 5.37% - Business Standard Tribune - Edge Therapeutics Incorporated (NASDAQ:EDGE) Short Interest Increased By 5.37%Business Standard TribuneEdge Therapeutics, Inc. is a United States biotechnology company, which focuses on developing therapies in the management of acute, life-threatening neurological conditions. The company has a market cap of $255.94 million. The Firm offers Precisa, ...and more »
About Edge Therapeutics

Edge Therapeutics logoEdge Therapeutics, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. The Company's product candidates include EG-1962 and EG-1964. The Company's lead product candidate, EG-1962, is initially being developed to improve clinical outcomes following subarachnoid hemorrhage (SAH) by administration through an external ventricular drain (EVD). Its second product candidate, EG-1964, contains aprotinin, a pancreatic trypsin inhibitor initially marketed as Trasylol, and is being developed using its Precisa development platform for the management of chronic subdural hematoma (cSDH), as a prophylactic treatment to prevent recurrent bleeding. Its product candidates utilize its Precisa development platform, which allows the Company to create therapeutics that are based on specific physical and chemical properties.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EDGE
  • CUSIP:
Key Metrics:
  • Previous Close: $8.78
  • 50 Day Moving Average: $8.83
  • 200 Day Moving Average: $9.36
  • P/E Ratio: N/A
  • P/E Growth: -0.07
  • Market Cap: $252.99M
  • Current Quarter EPS Consensus Estimate: $-1.50 EPS
Additional Links:
Edge Therapeutics (NASDAQ:EDGE) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha